Phase I study of oral vinorelbine in combination with erlotinib in advanced non-small cell lung cancer (NSCLC) using two different schedules

• Main Authors: Sutiman N., Zhang Z., Ang M.K., Tan S.-W.D., Toh C.K., Ng Q.S., Chowbay B., Lim W.-T.
• Other Authors: DUKE-NUS MEDICAL SCHOOL
• Format: Article
• Published: 2019
• Subjects: erlotinib; navelbine; antineoplastic agent; OSI-420; quinazoline derivative; vinblastine; vinorelbine tartrate; adult; advanced cancer; aged; alopecia; anemia; anorexia; area under the curve; arthralgia; Article; cancer fatigue; clinical article; clinical effectiveness; constipation; controlled study; diarrhea; dizziness; drug dose escalation; drug efficacy; drug response; drug safety; drug tolerability; dry eye; dry skin; dysphagia; face pain; febrile neutropenia; female; heartburn; human; hyponatremia; infection; keratitis; loss of appetite; male; maximum plasma concentration; myalgia; nail disease; nausea; neuropathy; neutropenia; non small cell lung cancer; nose disease; outcome assessment; paronychia; phase 1 clinical trial; pruritus; rash; steady state; stomatitis; vomiting; analogs and derivatives; Carcinoma, Non-Small-Cell Lung; clinical trial; drug administration; middle aged; treatment outcome; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Quinazolines; Treatment Outcome; Vinblastine
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/161571
• Institution: National University of Singapore

10.1371/journal.pone.0154316